Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SYS6023 in Advanced Solid Tumors
NCT07110883Phase 1Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYS6023 in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 2 more (7 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicity at 21 days, Number of Participants Reporting Adverse Events and Serious Adverse Events up to 2 years and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
SYS6023
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)ovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07110883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110883.